Evogene (EVGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EVGN Stock Forecast

Evogene stock forecast is as follows: an average price target of $12.00 (represents a 830.23% upside from EVGN’s last price of $1.29) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

EVGN Price Target

The average price target for Evogene (EVGN) is $12.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 830.23% upside from EVGN's last price of $1.29.

EVGN Analyst Ratings

Buy

According to 7 Wall Street analysts, Evogene's rating consensus is 'Buy'. The analyst rating breakdown for EVGN stock is 1 'Strong Buy' (14.29%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Evogene Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 23, 2024	Ben Klieve	Lake Street	$12.00	$3.54	239.24%	830.23%

The latest Evogene stock forecast, released on Aug 23, 2024 by Ben Klieve from Lake Street, set a price target of $12.00, which represents a 239.24% increase from the stock price at the time of the forecast ($3.54), and a 830.23% increase from EVGN last price ($1.29).

Evogene Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$12.00
Last Closing Price	$1.29	$1.29	$1.29
Upside/Downside	-100.00%	-100.00%	830.23%

In the current month, the average price target of Evogene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evogene's last price of $1.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 23, 2024	Lake Street	Buy	Buy	Hold
Jun 27, 2024	Alliance Global Partners	Buy	Buy	Hold
Aug 18, 2023	Lake Street	Buy	Buy	Hold
May 02, 2023	JMP Securities		Market Outperform	Initialise
May 02, 2023	UBS		Buy	Initialise
May 02, 2023	Raymond James		Strong Buy	Initialise
May 02, 2023	Lake Street		Buy	Initialise
May 02, 2023	Northcoast Research		Neutral	Initialise
May 26, 2022	RBC Capital	Outperform	Outperform	Hold

Evogene's last stock rating was published by Lake Street on Aug 23, 2024. The company gave EVGN a "Buy" rating, the same as its previous rate.

Evogene Financial Forecast

Evogene Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16	Mar 15	Mar 14
Revenue	-	-	-	-	-	-	-	-	-	-	-	$641.00K	$660.00K	$466.00K	$312.00K	$237.00K	$311.00K	$151.00K	$135.00K	$333.00K	$116.00K	$97.00K	$192.00K	$348.00K	$721.00K	$2.02M	$2.70M	$3.86M
Avg Forecast	$5.00M	$2.50M	$1.50M	$4.00M	$3.63M	$2.85M	$775.00K	$3.38M	$475.00K	$1.20M	$885.00K	$685.00K	$450.00K	$234.67K	$230.67K	$309.00K	$184.33K	$112.00K	$218.00K	$300.00K	$25.20M	$15.80M	$18.00M	$21.00M	$682.11K	$1.71M	$3.95M	$5.15M
High Forecast	$5.08M	$2.54M	$1.52M	$4.07M	$3.75M	$2.90M	$787.70K	$3.43M	$482.79K	$1.20M	$899.51K	$696.23K	$457.38K	$234.67K	$230.67K	$309.00K	$184.33K	$112.00K	$218.00K	$300.00K	$25.20M	$15.80M	$18.00M	$21.00M	$818.52K	$2.05M	$4.74M	$6.18M
Low Forecast	$4.92M	$2.46M	$1.48M	$3.93M	$3.50M	$2.80M	$762.29K	$3.32M	$467.21K	$1.20M	$870.49K	$673.77K	$442.62K	$234.67K	$230.67K	$309.00K	$184.33K	$112.00K	$218.00K	$300.00K	$25.20M	$15.80M	$18.00M	$21.00M	$545.68K	$1.37M	$3.16M	$4.12M
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	5	5	5	5	13	11	11	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.94%	1.47%	1.99%	1.35%	0.77%	1.69%	1.35%	0.62%	1.11%	0.00%	0.01%	0.01%	0.02%	1.06%	1.18%	0.68%	0.75%

Evogene's average Quarter revenue forecast for Jun 23 based on 1 analysts is $885.00K, with a low forecast of $870.49K, and a high forecast of $899.51K. EVGN's average Quarter revenue forecast represents a 38.07% increase compared to the company's last Quarter revenue of $641.00K (Mar 23).

Evogene EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16	Mar 15	Mar 14
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	5	5	5	5	13	11	11	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-5.85M	$-2.97M	$-6.26M	$-6.95M	$-7.33M	$-7.59M	$-6.89M	$-5.62M	$-5.13M	$-5.74M	$-3.18M	$-3.31M	$-2.79M	$-3.99M	$-2.66M	$-2.53M	$-1.46M
Avg Forecast	$-5.00M	$-2.50M	$-1.50M	$-4.00M	$-3.63M	$-2.85M	$-775.00K	$-8.57M	$-475.00K	$-1.20M	$-885.00K	$-6.77M	$-4.74M	$-234.67K	$-230.67K	$-5.35M	$-184.33K	$-112.00K	$-218.00K	$-5.41M	$-25.20M	$-15.80M	$-18.00M	$-21.00M	$-3.66M	$-1.28M	$-2.68M	$-1.91M
High Forecast	$-4.92M	$-2.46M	$-1.48M	$-3.93M	$-3.50M	$-2.80M	$-762.29K	$-6.85M	$-467.21K	$-1.20M	$-870.49K	$-5.42M	$-3.79M	$-234.67K	$-230.67K	$-4.28M	$-184.33K	$-112.00K	$-218.00K	$-4.33M	$-25.20M	$-15.80M	$-18.00M	$-21.00M	$-2.93M	$-1.03M	$-2.14M	$-1.53M
Low Forecast	$-5.08M	$-2.54M	$-1.52M	$-4.07M	$-3.75M	$-2.90M	$-787.70K	$-10.28M	$-482.79K	$-1.20M	$-899.51K	$-8.13M	$-5.68M	$-234.67K	$-230.67K	$-6.43M	$-184.33K	$-112.00K	$-218.00K	$-6.50M	$-25.20M	$-15.80M	$-18.00M	$-21.00M	$-4.39M	$-1.54M	$-3.21M	$-2.30M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.86%	0.63%	26.67%	30.13%	1.37%	41.16%	61.56%	25.78%	0.95%	0.23%	0.20%	0.18%	0.13%	1.09%	2.07%	0.94%	0.76%

undefined analysts predict EVGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Evogene's previous annual EBITDA (undefined) of $NaN.

Evogene Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16	Mar 15	Mar 14
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	5	5	5	5	13	11	11	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-6.98M	$-3.82M	$-7.16M	$-9.75M	$-9.11M	$-8.08M	$-7.61M	$-6.21M	$-6.60M	$-6.08M	$-4.23M	$-4.09M	$-3.71M	$-4.85M	$-3.37M	$-3.41M	$-2.34M
Avg Forecast	$-3.60M	$-4.59M	$-5.11M	$-4.24M	$-4.21M	$-5.87M	$-7.26M	$-10.91M	$-8.13M	$-9.10M	$-10.16M	$-8.62M	$-4.98M	$-10.01M	$-9.67M	$-6.81M	$-10.18M	$-8.99M	$-8.40M	$-6.97M	$17.31M	$9.16M	$9.67M	$15.27M	$-4.58M	$-2.76M	$-4.49M	$-2.92M
High Forecast	$-3.52M	$-4.49M	$-5.00M	$-4.15M	$-4.01M	$-5.74M	$-7.10M	$-8.72M	$-7.96M	$-8.90M	$-9.95M	$-6.90M	$-3.99M	$-10.01M	$-9.67M	$-5.45M	$-10.18M	$-8.99M	$-8.40M	$-5.58M	$17.31M	$9.16M	$9.67M	$15.27M	$-3.66M	$-2.21M	$-3.59M	$-2.34M
Low Forecast	$-3.68M	$-4.69M	$-5.22M	$-4.33M	$-4.41M	$-5.99M	$-7.41M	$-13.09M	$-8.30M	$-9.29M	$-10.38M	$-10.34M	$-5.98M	$-10.01M	$-9.67M	$-8.18M	$-10.18M	$-8.99M	$-8.40M	$-8.36M	$17.31M	$9.16M	$9.67M	$15.27M	$-5.50M	$-3.31M	$-5.38M	$-3.51M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.81%	0.77%	0.72%	1.01%	1.34%	0.79%	0.85%	0.74%	0.95%	-0.35%	-0.46%	-0.42%	-0.24%	1.06%	1.22%	0.76%	0.80%

Evogene's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EVGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Evogene SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16	Mar 15	Mar 14
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	5	5	5	5	13	11	11	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	$2.31M	$2.83M	$1.55M	$1.68M	$1.59M	$2.72M	$2.78M	$2.47M	$2.02M	$1.75M	$1.33M	$1.31M	$1.40M	$1.33M	$1.36M	$1.46M	$1.26M
Avg Forecast	$25.85M	$12.92M	$7.75M	$20.68M	$18.74M	$14.73M	$4.01M	$3.30M	$2.46M	$6.19M	$4.58M	$3.54M	$2.33M	$1.21M	$1.19M	$1.60M	$952.98K	$579.02K	$1.13M	$1.55M	$130.28M	$81.68M	$93.06M	$108.57M	$3.53M	$1.11M	$1.92M	$1.57M
High Forecast	$26.27M	$13.14M	$7.88M	$21.02M	$19.39M	$14.98M	$4.07M	$3.96M	$2.50M	$6.19M	$4.65M	$3.60M	$2.36M	$1.21M	$1.19M	$1.60M	$952.98K	$579.02K	$1.13M	$1.55M	$130.28M	$81.68M	$93.06M	$108.57M	$4.23M	$1.33M	$2.30M	$1.89M
Low Forecast	$25.43M	$12.71M	$7.63M	$20.34M	$18.09M	$14.49M	$3.94M	$2.64M	$2.42M	$6.19M	$4.50M	$3.48M	$2.29M	$1.21M	$1.19M	$1.60M	$952.98K	$579.02K	$1.13M	$1.55M	$130.28M	$81.68M	$93.06M	$108.57M	$2.82M	$886.91K	$1.54M	$1.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.65%	1.21%	1.28%	1.41%	1.00%	2.85%	4.80%	2.19%	1.30%	0.01%	0.02%	0.01%	0.01%	0.38%	1.23%	0.76%	0.80%

Evogene's average Quarter SG&A projection for Jun 23 is $4.58M, based on 1 Wall Street analysts, with a range of $4.50M to $4.65M. The forecast indicates a 97.64% rise compared to EVGN last annual SG&A of $2.31M (Mar 23).

Evogene EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16	Mar 15	Mar 14
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	5	5	5	5	13	11	11	15
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.17	$-0.09	$-0.17	$-0.24	$-0.22	$-0.20	$-0.19	$-0.15	$-0.17	$-0.24	$-0.16	$-0.16	$-0.15	$-0.19	$-0.13	$-0.13	$-0.09
Avg Forecast	$-0.62	$-0.79	$-0.88	$-0.73	$-0.72	$-1.01	$-1.25	$-0.95	$-1.40	$-1.57	$-1.75	$-1.60	$-2.00	$-1.97	$-1.90	$-1.80	$-2.00	$-1.77	$-1.65	$-1.80	$3.40	$1.80	$1.90	$3.00	$-0.17	$-0.09	$-0.25	$-0.15
High Forecast	$-0.61	$-0.77	$-0.86	$-0.71	$-0.69	$-0.99	$-1.22	$-0.93	$-1.37	$-1.53	$-1.71	$-1.57	$-1.96	$-1.97	$-1.90	$-1.80	$-2.00	$-1.77	$-1.65	$-1.80	$3.40	$1.80	$1.90	$3.00	$-0.14	$-0.07	$-0.20	$-0.12
Low Forecast	$-0.63	$-0.81	$-0.90	$-0.75	$-0.76	$-1.03	$-1.28	$-0.97	$-1.43	$-1.60	$-1.79	$-1.63	$-2.04	$-1.97	$-1.90	$-1.80	$-2.00	$-1.77	$-1.65	$-1.80	$3.40	$1.80	$1.90	$3.00	$-0.20	$-0.11	$-0.30	$-0.18
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.11%	0.05%	0.09%	0.13%	0.12%	0.10%	0.11%	0.09%	0.09%	-0.07%	-0.09%	-0.08%	-0.05%	1.12%	1.44%	0.52%	0.63%

According to undefined Wall Street analysts, Evogene's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EVGN previous annual EPS of $NaN (undefined).

Evogene Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVGN	Evogene	$1.27	$12.00	844.88%	Buy
CKPT	Checkpoint Therapeutics	$3.72	$20.00	437.63%	Buy
CLGN	CollPlant Bio	$3.64	$12.50	243.41%	Buy
FATE	Fate Therapeutics	$1.88	$5.00	165.96%	Buy
CGEN	Compugen	$1.59	$4.00	151.57%	Buy
ALDX	Aldeyra Therapeutics	$5.33	$12.00	125.14%	Buy
RCUS	Arcus Biosciences	$16.08	$31.71	97.20%	Buy
CRVS	Corvus Pharmaceuticals	$7.39	$12.50	69.15%	Buy

EVGN Forecast FAQ

Is Evogene a good buy?

Yes, according to 7 Wall Street analysts, Evogene (EVGN) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 85.71% of EVGN's total ratings.

What is EVGN's price target?

Evogene (EVGN) average price target is $12 with a range of $12 to $12, implying a 830.23% from its last price of $1.29. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Evogene stock go up soon?

According to Wall Street analysts' prediction for EVGN stock, the company can go up by 830.23% (from the last price of $1.29 to the average price target of $12), up by 830.23% based on the highest stock price target, and up by 830.23% based on the lowest stock price target.

Can Evogene stock reach $2?

EVGN's average twelve months analyst stock price target of $12 supports the claim that Evogene can reach $2 in the near future.

What are Evogene's analysts' financial forecasts?

Evogene's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.62M (high $10.86M, low $10.39M), average EBITDA is $-15.819M (high $-13.92M, low $-17.717M), average net income is $-28.239M (high $-25.575M, low $-30.903M), average SG&A $40.78M (high $42.39M, low $39.17M), and average EPS is $-3.935 (high $-3.832, low $-4.038). EVGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13M (high $13.21M, low $12.79M), average EBITDA is $-13M (high $-12.787M, low $-13.213M), average net income is $-17.538M (high $-17.164M, low $-17.911M), average SG&A $67.21M (high $68.31M, low $66.11M), and average EPS is $-3.02 (high $-2.956, low $-3.084).

Did the EVGN's actual financial results beat the analysts' financial forecasts?

Based on Evogene's last annual report (Dec 2022), the company's revenue was $1.68M, beating the average analysts forecast of $1.22M by 36.81%. Apple's EBITDA was $-23.845M, beating the average prediction of $-10.556M by 125.90%. The company's net income was $-29.844M, missing the average estimation of $-31.485M by -5.21%. Apple's SG&A was $10.42M, beating the average forecast of $6.33M by 64.54%. Lastly, the company's EPS was $-0.72, missing the average prediction of $-7.667 by -90.61%. In terms of the last quarterly report (Mar 2023), Evogene's revenue was $641K, missing the average analysts' forecast of $685K by -6.42%. The company's EBITDA was $-5.847M, missing the average prediction of $-6.774M by -13.68%. Evogene's net income was $-6.981M, missing the average estimation of $-8.621M by -19.02%. The company's SG&A was $2.32M, missing the average forecast of $3.54M by -34.63%. Lastly, the company's EPS was $-0.17, missing the average prediction of $-1.6 by -89.38%